Back to results
RecruitingPhase 2

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

NCT05761470

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

First Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

View on ClinicalTrials.gov
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation — TrialFind